Previous 10 | Next 10 |
Independent DSMB recommends continuing clinical trial of Berubicin without modification Enrollment expected to be complete in early Q1 2024 HOUSTON, TX / ACCESSWIRE / December 18, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (CNS or the Company), a biopharmaceutical company specia...
A group of researchers recently convened at an event organized by the John B. Little (JBL) Center for Radiation Sciences to discuss strategies for mitigating the side effects of brain cancer radiotherapy. Radiation therapy is one of the core pillars of brain-cancer treatment alongside chemoth...
2023-12-08 17:35:51 ET More on CNS Pharmaceuticals Financial information for CNS Pharmaceuticals For further details see: CNS Pharmaceuticals files to sell 3.81M shares of common stock
CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company focused on developing innovative therapies for central nervous system disorders, specifically aggressive brain cancers. In September , the company announced that 200 out of 243 expected patients had been enrolled in its ongoing s...
HOUSTON, TX / ACCESSWIRE / December 6, 2023 / Every form of cancer is devastating, but the unfortunate reality is not all cancers are created equal. There are certain forms of cancer that are more deadly. Glioblastoma (GBM) is a highly aggressive type of brain cancer with no cure, leading to a g...
A recent review of research papers on brain cancers that have metastasized to the lungs has discovered that already-approved treatments could be clinically tested as potential therapies against brain metastasis. The University of Bristol study also discovered genetic differences between smoke...
CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has announced the presentation of updated safety data from its ongoing potentially pivotal study evaluat...
CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has announced the presentation of updated safety data from its ongoing potentially pivotal study evaluat...
Data presented at the Society of NeuroOncology (SNO) 28 th Annual Meeting Berubicin currently being evaluated in an ongoing potentially pivotal study for the treatment of Glioblastoma Multiforme (GBM) Topline result from preplanned interim futility analysis on track for December 2023 ...
Medulloblastoma is a rare type of brain tumor that is primarily found in children. It is estimated that about 350 cases of this illness are diagnosed annually. This cancer often resists treatment, which involves a combination of radiation, surgery and chemotherapy. This, combined with the diseas...
News, Short Squeeze, Breakout and More Instantly...
CNS Pharmaceuticals Inc. Company Name:
CNSP Stock Symbol:
NYSE Market:
Shares of Ovid Therapeutics Inc (NASDAQ:OVID) dipped 65.7% to $1.1285 after Takeda’s Skyline study in Dravet syndrome missed its primary endp...
CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has entered into securities purchase agreements with health-care focused institutional investors. The ag...
Shares of AMMO, Inc. (NASDAQ:POWW) fell sharply during Friday's session following fourth-quarter results. AMMO reported a fourth-quarter profi...